2024-04-19 14:34:50 ET
Summary
- Corbus Pharmaceuticals is a biotech stock focused on precision oncology, with its flagship research project targeting Nectin-4-positive solid tumors.
- The company is running low on funds and has filed with the SEC to raise up to $300 million, which may cause dilution for investors.
- Early clinical results for CRB-701 are promising. Its good safety profile and efficacy hint at a significant potential market impact.
- While the underlying research is exciting, the stock is a "hold" until more tangible clinical trial data is available due to the low odds of FDA approval in oncology.
Corbus Pharmaceuticals Holdings, Inc. ( CRBP ) is a biotech stock for investors seeking to gain oncology exposure. Their flagship research project is CRB-701, a Phase 1 drug that targets Nectin-4-positive solid tumors. CRBP also has other research projects that could be lucrative, but all of them are still in their stages and largely unproven....
Read the full article on Seeking Alpha
For further details see:
Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncology